AVBP vs EFX · $1.39B cap vs P/E 54, rev $3.35B
ArriVent BioPharma, Inc. Common Stock (AVBP) versus Equifax Inc (EFX) — a side-by-side from cached financials, not a winner call.
ArriVent BioPharma, Inc. Common Stock (AVBP) is a biotechnology company listed on US.
Equifax Inc (EFX) is a consulting services company listed on US.
AVBP does not have a complete income-statement cache yet.
Latest reported EFX revenue for 2026-06-30 was $3.35B. Net income was $355.4M. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
AVBP currently screens at market cap $1.39B. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Not investment advice. Open the AVBP and EFX stock pages for the full models.
Not investment advice.